Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

NeuroQure

Financiado

Neuroprotective human antibodies to the flexible tail of the prion protein

The misfolding of the cellular prion protein (PrPC) causes infectious neurodegenerative conditions called prion diseases. In the framework of the ERC-funded study The Prion Protein in Health and Disease the team of Adriano Aguzzi... ver más

28/02/2019

UZH

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITAT ZURICH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-02-28

ERC-2017-PoC: ERC-Proof of Concept

I+D

Cerrada hace 7 años

0% 100% 100%

2 Participantes

UZH

150.00K€ | Lider

Peymo Peralta, S.L.

465.60K€ | Participante

Últimas noticias

02-12-2024: AGENCIA-VALENCIANA-D... En las últimas 48 horas el Organismo AGENCIA VALENCIANA D... ha otorgado 1 concesiones

02-12-2024: CDTI En las últimas 48 horas el Organismo CDTI ha otorgado 4 concesiones

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2017-08-21
Fecha Fin: 2019-02-28

Líder del proyecto

UNIVERSITAT ZURICH

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto The misfolding of the cellular prion protein (PrPC) causes infectious neurodegenerative conditions called prion diseases. In the framework of the ERC-funded study The Prion Protein in Health and Disease the team of Adriano Aguzzi has discovered that antibodies against the flexible tail (FT) of PrPC are neuroprotective against prion pathologies. Here we propose to clone and express such antibodies from humans and to develop them as antiprion therapeutics. The principal investigator has founded a company (www.Mabylon.com) which has established a high-yield method for cloning paired heavy and light chains from human memory B cells. The proposed research program will identify rare anti-FT immunoreactive individuals among large populations by high-throughput screening. The clinical information of the selected individuals will help to identify antibodies from persons devoid of pathologies that may be related to anti-PrPC autoimmunity. Therefore, the human antibodies generated within this program will represent fast-track investigational new drug (IND) candidates with safety profiles superior to those of murine or humanized antibodies. Completion of the proposed activities will lead to the development of therapies against prion diseases, which are currently considered untreatable and invariably fatal.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores